Back to News
Market Impact: 0.45
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Source: Business Wire
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The FDA approved Merck's WELIREG in combination with Eisai's LENVIMA for certain previously treated adult patients with advanced clear-cell renal cell carcinoma. The approval expands the treatment options and commercial opportunity for both companies in a high-value oncology indication.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
MRK0.85
More News
- H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation
- OpenAI rogue agents leaked 53 images from ChatGPT users and reportedly created nearly 1 million links packing encoded bits of info
- Facebook found liable as TikTok settles for $100m over user safety
- What would a US diesel export ban mean for global fuel prices?
- Appeals court rules that states can regulate Kalshi’s sports prediction markets, dealing another legal blow to platforms
- US court rules against Kalshi, says states can regulate prediction markets